Insights Ahead: Kymera Therapeutics's Quarterly Earnings
Portfolio Pulse from Benzinga Insights
Kymera Therapeutics (NASDAQ:KYMR) is set to release its quarterly earnings on October 31, 2024. Analysts expect an EPS of $-0.84. The company previously beat EPS estimates, resulting in a share price increase. Analysts rate Kymera as 'Outperform' with a price target of $52.8, indicating an 8.89% upside. Kymera's revenue growth and gross profit lag behind peers, but it shows strong net margin and ROE. The company's debt-to-equity ratio is below industry average, indicating conservative financial management.
October 30, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kymera Therapeutics is expected to announce its quarterly earnings with an anticipated EPS of $-0.84. The company has a consensus 'Outperform' rating and a price target of $52.8, suggesting an 8.89% upside. Previous earnings beat led to a share price increase.
Kymera's upcoming earnings release is highly anticipated, with analysts expecting a negative EPS. The company's previous earnings beat resulted in a share price increase, indicating potential positive movement if estimates are surpassed again. The 'Outperform' rating and price target suggest optimism among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100